论文部分内容阅读
目的:观察西格列汀联合门冬胰岛素30治疗2型糖尿病的有效性及安全性。方法:将口服降糖药治疗效果差且病程较长的2型糖尿病患者80例随机分为实验组和对照组各40例。实验组给予西格列汀联合门冬胰岛素30治疗,对照组给予门冬胰岛素30胰岛素治疗。观察2组患者治疗第0,8,16周时FBG(空腹血糖)、2hBG(餐后2h血糖)、HbA1c(糖化血红蛋白)、胰岛素用量和BMI值。第16周时检测2组患者C肽水平,并进行比较。结果:治疗后8、16周后,2组患者的FBG、2hBG和HbA1c均显著下降,与治疗前相比差异具有显著性(P<0.05)。同时实验组FBG、2hBG和HbA1c较对照组显著下降(P<0.05)。治疗16周后,实验组的BMI和胰岛素用量均显著低于对照组,而C肽水平显著高于对照组(P<0.05)。结论:口服降糖药治疗效果差且病程较长的2型糖尿病应用西格列汀联合门冬胰岛素30可获得良好的血糖控制,同时可改善胰岛功能,减少体质量增加,减少低血糖发生,安全有效。
Objective: To observe the efficacy and safety of sitagliptin and insulin aspart 30 in type 2 diabetes mellitus. Methods: 80 patients with type 2 diabetes mellitus who had poor therapeutic effect and longer course of oral hypoglycemic agents were randomly divided into experimental group and control group (n = 40). The experimental group was treated with sitagliptin plus insulin aspart 30, and the control group with insulin aspart 30 insulin. FBG (fasting blood glucose), 2hBG (2h postprandial blood glucose), HbA1c (HbA1c), insulin dosage and BMI were observed at 0, 8 and 16 weeks after treatment. At week 16, C-peptide levels in both groups were tested and compared. Results: At 8 and 16 weeks after treatment, the FBG, 2hBG and HbA1c in two groups were significantly decreased compared with those before treatment (P <0.05). At the same time, FBG, 2hBG and HbA1c in experimental group were significantly lower than those in control group (P <0.05). After 16 weeks of treatment, the experimental group BMI and insulin dosage were significantly lower than the control group, while the C-peptide levels were significantly higher than the control group (P <0.05). Conclusion: Oral hypoglycemic agents with poor response and longer duration of type 2 diabetes, sitagliptin and insulin aspart 30 can be obtained good glycemic control, and can improve pancreatic islet function, reduce body weight and reduce the incidence of hypoglycemia, Safe and effective.